Alumis Inc
ALMS4.720USD
0.000
Handelsschluss 11/07, 16:00（ET）Kurse um 15 Minuten verzögert
491.08MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Alumis Inc Unternehmen
Alumis Inc. is a clinical-stage biopharmaceutical company. It develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. It has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
Alumis Inc Informationen
BörsenkürzelALMS
Name des UnternehmensAlumis Inc
IPO-datumJun 28, 2024
CEOMr. Martin Babler
Anzahl der mitarbeiter168
WertpapierartOrdinary Share
GeschäftsjahresendeJun 28
Addresse280 East Grand Avenue
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94080
Telefon16502316625
Websitehttps://www.alumis.com/
BörsenkürzelALMS
IPO-datumJun 28, 2024
CEOMr. Martin Babler
Führungskräfte von Alumis Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Umsatzaufteilung
FY2025Q2
FY2025Q1
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
2.67M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Ayur Maya Capital Management Company, L.P.
15.63%
Foresite Capital Management, LLC
10.35%
Samsara BioCapital, LLC
4.96%
VenBio Partners LLC
4.77%
The Vanguard Group, Inc.
4.16%
Andere
60.14%
Aktionäre
Aktionäre
Anteil
Ayur Maya Capital Management Company, L.P.
15.63%
Foresite Capital Management, LLC
10.35%
Samsara BioCapital, LLC
4.96%
VenBio Partners LLC
4.77%
The Vanguard Group, Inc.
4.16%
Andere
60.14%
Aktionärstypen
Aktionäre
Anteil
Private Equity
34.07%
Investment Advisor
16.05%
Hedge Fund
12.54%
Investment Advisor/Hedge Fund
9.97%
Venture Capital
7.65%
Individual Investor
0.82%
Research Firm
0.78%
Bank and Trust
0.48%
Pension Fund
0.04%
Andere
17.59%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
192
79.50M
82.06%
+19.19M
2025Q2
152
55.51M
57.84%
+13.35M
2025Q1
136
45.24M
77.97%
+3.71M
2024Q4
112
45.08M
95.45%
+8.63M
2024Q3
90
35.83M
75.90%
+3.97M
2024Q2
36
30.85M
69.04%
+30.85M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Ayur Maya Capital Management Company, L.P.
15.14M
15.63%
--
--
Jun 30, 2025
Foresite Capital Management, LLC
10.03M
10.35%
-5.17M
-34.02%
Jun 30, 2025
Samsara BioCapital, LLC
4.80M
4.96%
--
--
Jun 30, 2025
VenBio Partners LLC
4.62M
4.77%
+1.83M
+65.74%
Jun 30, 2025
The Vanguard Group, Inc.
3.40M
3.51%
+2.47M
+263.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.81M
3.93%
+2.46M
+182.05%
Jun 30, 2025
Trium Capital LLP
2.65M
2.73%
+2.65M
--
Jun 30, 2025
Nextech Invest, Ltd.
2.92M
3.01%
+1.44M
+97.43%
Jun 30, 2025
Cormorant Asset Management, LP
2.15M
2.22%
--
--
Jun 30, 2025
Tang Capital Management, LLC
2.00M
2.06%
+2.00M
--
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Micro-Cap ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Mehr Anzeigen
ProShares Ultra Nasdaq Biotechnology
Anteil0.04%
iShares Micro-Cap ETF
Anteil0.04%
Invesco Nasdaq Biotechnology ETF
Anteil0.04%
iShares Biotechnology ETF
Anteil0.03%
iShares Russell 2000 Value ETF
Anteil0.02%
iShares Russell 2000 ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
Global X Russell 2000 ETF
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
